Prevalence of type B and non-A, non-B hepatitis in hemophilia: Relationship to chronic liver disease

Kim, Hugh C.; Saidi, Parvin; Ackley, Alexander; Bringelsen, Karen A.; Gocke, David J.

doi:10.1016/0016-5085(80)90908-7

Cited by 49 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twentythree of the 59 patients had increased ALT levels, while only 5 had hepatitis B surface antigen. This points to non-A, non-B hepatitis in a substantial part of the study population, and is in accordance with previous studies in haemophiliacs (18). Anti bodies against CMV but not against EBV were elevated in the patients compared to the controls, similar to the findings of Landay et al (6).…”

Section: Discussionsupporting

confidence: 93%

Immunological Alterations in Haemophiliacs Treated with Lyophilized Factor VIII Cryoprecipitate from Volunteer Donors

et al. 1984

View full text Add to dashboard Cite

SummaryWe studied immune function in Belgian haemophiliacs treated with Factor VIII from volunteer donors. No patient had clinical evidence of immune deficiency. We found a decrease in T-helper cells (p <0.0005), in the ratio of T-helper over T-cytotoxic/ suppressor cells (1.72 ± 0.47 versus 2.24 ± 0.82 in controls, p <0.005) and in lymphocyte responsiveness to mitogens (p <0.05).These findings could not be linked to the amount of F VIII received over the last year, the time since last F VIII administration, circulating immune complexes (54% positive patients, 7% positive controls, p <0.005), increased ALT levels, antibodies to cytomegalo-virus (85% of the patients, 45% of the controls, p <0.005), antibodies to Epstein-Barr virus, nor to the presence of HLA-DR 5 which was found in 56% of the haemophiliacs (20% of the overall Belgian population, p <0.005).Either F VIII induces long lasting immunological alterations unrelated to AIDS, or haemophilia is itself associated with such changes.

show abstract

Section: Discussionsupporting

confidence: 93%

Immunological Alterations in Haemophiliacs Treated with Lyophilized Factor VIII Cryoprecipitate from Volunteer Donors

et al. 1984

View full text Add to dashboard Cite

show abstract

“…While concentrates of human coagulation factor IX have proven life-saving in the treatment of patients deficient in this protein, their use has been associated with at least two significant adverse effects. Firstly, they carry a risk of transmitting viral diseases, particularly hepatitis (Aronson, 1979;Rossiter et al 1979: Kim et al, 1980Gerety & Aronson. 1982;Gurtler et al, 1984;Kernoff et al 1985;Mannucci et al 1985a) and human T-cell lymphotropic viruses (HTLV) (Ramsey et al, 1984: Levine.…”

mentioning

confidence: 99%

Studies on the effect of heat treatment on the thrombogenicity of factor IX concentrates in dogs

et al. 1987

View full text Add to dashboard Cite

This study examines the effects of heat treatment for 72 h at 80 degrees C on the potential thrombogenicity of lyophilized human coagulation factor IX concentrates. Since heating generated minor amounts of thrombin, concentrate was prepared with antithrombin III addition prior to heat treatment. Changes in coagulation parameters were followed prior to and after infusion of 100 iu/kg of heated and unheated concentrates to dogs. All batches produced a transient fall in platelet count during infusion and a delayed rise in plasma fibrinopeptide A, accompanied by a minor prolongation of the activated partial thromboplastin time. Such changes were less marked for heated batches. Control infusion of a 'failed' factor IX concentrate showed an additional fall in fibrinogen, rise in fibrin degradation products and a more rapid rise in fibrinopeptide A, while thrombin infusion caused an even more dramatic intravascular coagulation. These studies indicated no increase in the potential thrombogenicity of freeze dried factor IX concentrates as a result of heat treatment.

show abstract

“…DDAVP would easily induce the release of "normal" vWF from these tissue stores, although the disappearance time of the elevated vWF might be shorter than those in patients with inherited type I von Willebrand disease [ 131. Transfusion of blood products is associated with certain risks such as for viral hepatitis (hepatitis B and non-A,non-B hepatitis) [31] and acquired immune deficiency syndrome [32,33]. We conclude that treatment with DDAVP is safe and effective and has major advantages over treatment with blood products in patients with acquired von Willebrand syndrome.…”

Section: Discussionmentioning

confidence: 83%

DDAVP in acquired von Willebrand syndrome associated with multiple myeloma

et al. 1986

View full text Add to dashboard Cite

The response to a single intravenous infusion of 1-deamino-8-D-arginine vasopressin (DDAVP, desmopressin) was studied in two patients with acquired von Willebrand syndrome associated with IgG-kappa myeloma. Following infusion of DDAVP (0.3-0.4 micrograms/kg), prolonged bleeding time was normalized; plasma ristocetin cofactor activity, von Willebrand factor antigen, and factor VIII activity were remarkably increased; and high-molecular-weight forms of von Willebrand factor were demonstrated by crossed immunoelectrophoresis in both patients. Excellent hemostasis was achieved following administration of DDAVP in one patient when it was used for the treatment of gum bleeding and for the prophylaxis of bleeding during and after dental extractions. These observations suggest that DDAVP is an effective alternative to blood products for at least some patients with acquired von Willebrand syndrome in addition to patients with inherited von Willebrand disease, hemophilia A, and uremia.

show abstract

Prevalence of type B and non-A, non-B hepatitis in hemophilia: Relationship to chronic liver disease

Cited by 49 publications

References 36 publications

Immunological Alterations in Haemophiliacs Treated with Lyophilized Factor VIII Cryoprecipitate from Volunteer Donors

Immunological Alterations in Haemophiliacs Treated with Lyophilized Factor VIII Cryoprecipitate from Volunteer Donors

Studies on the effect of heat treatment on the thrombogenicity of factor IX concentrates in dogs

DDAVP in acquired von Willebrand syndrome associated with multiple myeloma

Contact Info

Product

Resources

About